

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Soares et al

Appln. No.: 10/589,054

Filed: April 1, 2008

For: Amylin Family Peptides and Methods
for Using Them for Treatment

Art Unit: 1646

Examiner: Zachary C. Howard

Atty. Docket: 0105US-UTL2

Confirm. No.: 5466

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Terminal Disclaimer

Amylin Pharmaceuticals, Inc. is the owner of the entire right, title and interest in US Application No. 10/589,054 filed April 1, 2008 ("the instant application") by virtue of Assignments recorded in the US Patent Office on February 14, 2007, at Reel 018892, Frame 0115 and on April 1, 2008, at Reel 020738, Frame 0005.

Amylin Pharmaceuticals, Inc. is the owner of the entire right, title and interest in US Patent No. 7,399,744 by virtue of Assignments recorded in the US Patent Office on May 20, 2004, at Reel 015373, Frame 0678.

Amylin Pharmaceuticals, Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration of the full statutory term of US Patent No. 7,399,744, as the term of this patent is presently shortened by any terminal disclaimer.

Amylin Pharmaceuticals, Inc. hereby agrees that any patent granted on the instant application shall be enforceable only for and during such period that it and US Patent No. 7,399,744 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, Amylin Pharmaceuticals, Inc. does not disclaim the terminal part of the term of any patent granted on the instant application that would extend beyond the expiration of the full statutory term of US Patent No. 7,399,744 in the event that US


Patent No. 7,399,744 expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or part under 37 CFR § 1.321, has all claims canceled by a reexamination certificate, is reissued, or is any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the instant application or any patent granted on the instant application.

The Commissioner is authorized to charge the fee of \$140 for recordation of this Terminal Disclaimer to Deposit Account No. 010535.

Dated: August 7, 2010

Respectfully submitted,
AMYLIN PHARMACEUTICALS, INC.


Edward D. Grief
Registration No. 38,898

AMYLIN PHARMACEUTICALS, INC.
9360 Towne Centre Drive
San Diego, CA 92121
Phone: 858-552-2200
Direct Dial: 858-754-4153